Rasha Al-Lamee
Latest contributions
FFRangio, are we ready for everyday practice?
02 Jun 2026
Register for free to this webinar on Wednesday 10 June at 5:00pm with R. Al-Lamee, W. Fearon and A. Kirtane and learn about the latest evidence supporting the use of FFRangio, and much more!
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
Publishing in interventional cardiology: aligning authors, editors and impact
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on publishing in interventional cardiology by aligning the expectations of authors, editors, reviewers, and readers. It addresses differences in paper interpretation, common misalignments between scientific intent and editorial outcomes, and strategies to enhance clarity, relevance, and impact of scientific publications.
Asymptomatic high-risk patients: can CT coronary angiography improve our practice?
21 May 2026 – From EuroPCR 2026
This session examines the role of cardiac computed tomography (CT) coronary angiography in improving clinical practice for asymptomatic high-risk patients. It discusses detection of vulnerable plaque features, the importance of inflammation and physiology in risk assessment, and explores individualized treatment pathways including PCI, medical therapy, or...
Evidence in action: advancing care for angina with Shockwave Reducer
20 May 2026 – From EuroPCR 2026
Despite major advances in coronary revascularisation and medical therapy, angina continues to represent a significant clinical burden, affecting both quality of life and long-term patient management.
This EuroPCR 2026 session explores the emerging role of the Shockwave Reducer as a therapeutic option in patients with persistent angina....
Renal denervation 360°: are you ready for the future?
20 May 2026 – From EuroPCR 2026
Where does renal denervation (RDN) stand today, and where is it heading next?
This EuroPCR 2026 session provides a comprehensive update on RDN, covering its safe and effective use in line with the latest European recommendations. Faculty members share practical guidance on patient selection, programme implementation, and...
Rethinking coronary artery disease: from ischaemia to atheroma - Implications of the Lancet Commission for Interventional Cardiology
20 May 2026 – From EuroPCR 2026
This session invites a re-evaluation of coronary artery disease by shifting focus from ischemia to atheroma, integrating insights from the Lancet Commission for Interventional Cardiology. It explores the significance of plaque burden, biology, and inflammation in guiding PCI decisions and outlines the future role of PCI...
New evidence for coronary physiology in epicardial disease
20 May 2026 – From EuroPCR 2026
Explore new evidence in coronary physiology related to epicardial disease through analyses of landmark trials and registries. Topics include five-year follow-up data from DEFINE-FLAIR and iFR-SWEDEHEART, complete revascularization in elderly myocardial infarction patients, angiography-derived versus pressure wire assessments, prognostic implications of CT angiography-derived physiology, and the...
IVUS and NIRS imaging: a pathway to improve outcomes in stable and acute coronary syndromes
19 May 2026 – From EuroPCR 2026
IVUS-guided PCI is well established in complex coronary interventions, but combining it with near-infrared spectroscopy (NIRS) is opening a new dimension by linking vessel geometry with plaque biology.
This EuroPCR 2026session explores how IVUS-NIRS imaging improves PCI planning and risk stratification in both stable and acute coronary...
Contemporary workflow for class IA PCI
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents a contemporary workflow for Class IA PCI, focusing on how coronary physiology can be used to better understand disease patterns and guide procedural strategy in complex interventions.
It explores the role of physiological assessment in refining decision-making, alongside new co- and tri-registration...
Physiology-guided PCI: LIVE Educational Case from Sant'Andrea University Hospital - Rome, Italy
19 May 2026 – From EuroPCR 2026
This educational session presents a live, physiology-guided PCI case from Sant'Andrea University Hospital, Rome. It emphasizes the role of integrated functional imaging in procedural planning, discusses treatment strategies for multivessel disease and long lesions, and demonstrates a step-by-step fractional flow reserve (FFR)-guided PCI approach.
Turning Point Podcast by Eurolntervention
17 Sep 2025
Turning Point: a new podcast series brought to you by EuroIntervention as part of our 20th anniversary celebration.
Coronary Interventions: EuroPCR 2025 highlights
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Rasha Al-Lamee, Nieves Gonzalo, and Thomas Cuisset highlighted key advances in coronary interventions, with a strong emphasis on managing complex cases—particularly calcified lesions.
Throughout the Course, LIVE cases and expert hotlines showcased dedicated devices and evolving strategies designed specifically for these challenging lesions. Advanced...
The new global era of patient care with CathWorks FFRangio
22 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session highlights how CathWorks FFRangio is reshaping coronary physiology assessment worldwide. Through case-based experience and real-world data, it showcases the integration of FFRangio into routine clinical workflows—from early adoption at Clinique Pasteur in Toulouse to implementation across the UK. The session also presents...
Coronary physiology: FFR and beyond
22 May 2025 – From EuroPCR 2025
Advance your understanding of coronary physiology with a focus on fractional flow reserve (FFR) and beyond. This session covers randomized trials comparing physiology-guided treatment to standard care in ANOCA, graft patency related to quantitative flow ratio, impacts of microvascular dysfunction on patient outcomes, and prognostic value...
Symplicity Spyral renal denervation: more insights from clinical practice
21 May 2025 – From EuroPCR 2025
Renal denervation is gaining momentum in the management of hypertension. This EuroPCR 2025 session brings together long-term clinical experience and practical guidance on using the Symplicity Spyral™ system. Learn how to apply the latest European guidelines in daily practice, pick up valuable procedural tips from over...
Complex multivessel disease - LIVE Case
21 May 2025 – From EuroPCR 2025
An 89-year-old male patient presented with stable angina, preserved LV function and some risk factors such as hypertension and diabetes. CT scan and angiography revealed occlusion of proximal RCA and bifurcation lesions on LAD and circumflex (medina 1,1,1). Operators treated the bifurcation lesions with provisional stenting.
Regarding...
Invasive treatment of refractory angina
20 May 2025 – From EuroPCR 2025
Explore invasive treatment options for refractory angina through clinical case presentations emphasizing coronary physiology guidance, coronary microvascular disease management, and innovative therapies such as coronary sinus reducer implantation. This session highlights provocative test-guided approaches to optimize patient outcomes.
Role of PCI in the contemporary management of patients with angina and coronary disease
17 May 2024 – From EuroPCR 2024
This session aims to generate awareness about the distinct phenotypes of coronary artery disease (focal, diffuse, serial) that can be identified through contemporary physiological tools, and the implications of these phenotypes on achieving successful functional PCI results. Participants will also discuss the considerations around using PCI...
Multivessel disease PCI guided by physiology and IVUS - LIVE case
16 May 2024 – From EuroPCR 2024
A 78-year-old woman with hypertension, dyslipidemia, and obesity, presented with angina CCS2 and preserved LV function. The coronary angiogram showed stenosis in the RCA (proximal and mid), CX, and calcified proximal and mid LAD involving D1 and D2.
The operators performed PCI on the RCA (1 stent)...
CathWorks FFRangio - Enhancing patient care
16 May 2024 – From EuroPCR 2024
Explore this EuroPCR 2024 session to gain an in-depth understanding of how FFRangio utilizes routine angiograms to provide valuable insights, delve into the integration of FFRangio-guided decisions for optimizing patient care, and examine the practical application of FFRangio in routine clinical practice, encompassing its benefits and challenges.
Personalised Vascular Care Award - Competition
16 May 2024 – From EuroPCR 2024
This session features a competition for the Personalised Vascular Care Award, showcasing selected abstracts on various aspects of personalised vascular care. The presentations cover topics such as the evaluation of myocardial bridges, the relationship between IMR and FFR, the use of contrast-derived indices of coronary microvascular...
The turning point in hypertension care: Symplicity Spyral renal denervation in practice
15 May 2024 – From EuroPCR 2024
Explore this session to grasp the FDA-approved status of renal denervation, its safety and efficacy shown in numerous studies with lasting effects, and the importance of multidisciplinary discussions for successful indications. Consult also the session for updated recommendations on renal denervation in hypertension treatment guidelines, procedural safety...
Hotline: advances in coronary physiology
14 May 2024 – From EuroPCR 2024
This hotline session explores the latest advancements in coronary physiology and their implications for percutaneous coronary intervention (PCI). Topics covered include the influence of pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI, the prognostic value of myocardial ischemic burden in STEMI...
After ORBITA 2, what is the role of PCI in the contemporary management of patients with angina and coronary disease?
16 May 2024 – From EuroPCR 2024
Emanuele Barbato interviews Rasha Al-Lamee, the principal investigator of the ORBITA 2 trial, about the current role of percutaneous coronary intervention (PCI). Unlike ORBITA 1, ORBITA 2 focused on the effects of angioplasty as a monotherapy, without prior anti-angina treatment. The results showed that angioplasty improved symptoms...
Coronary sinus reducer for the treatment of refractory angina: A randomised, placebo-controlled trial (ORBITA-COSMIC)
08 Apr 2024
Aaysha Cader interviews Rasha Al-Lamee and Michael Foley about the results of the ORBITA-COSMIC trial presented at ACC.24 in Atlanta.
Results showed that coronary sinus reducer relieved angina symptoms but lacked evidence of increased blood flow to the heart. While beneficial for refractory angina patients, its mechanism remains...
Author
Author
Author
ORBITA-2 - Percutaneous coronary intervention for stable angina: A randomized, placebo-controlled trial
12 Nov 2023
Luis Ortega Paz interviews Rasha Al-Lamee and Christopher Rajkumar on the results of ORBITA-2 randomized placebo-controlled trial, which were presented at the AHA 2023 Congress in Philadelphia.
Author
Author
Author
EuroPCR 2023 Hotlines/Late-Breaking Trials: focus on wire and image-based physiology
18 May 2023 – From EuroPCR 2023
Find out more about a series of studies focusing on wire and image based physiology: Coronary microvascular function and CT coronary angiography trial aiming to assess whether endotype diagnosis informed by coronay function testing vs angiography improved angina; a 5-year follow up of the DEFINE FLAIR;...
Multivessel disease - Which patients for PCI, CABG or medical treatment?
18 May 2023 – From EuroPCR 2023
In this series of slides, uncover optimal treatments for multivessel disease: Evaluate revascularisation necessity, pinpoint when CABG excels, and identify prime scenarios for PCI.
Physiologic guidance and optimisation in multivessel disease
16 May 2023 – From EuroPCR 2023
Follow the case study of this 70-year-old ex-smoker male patient with HTN, dyslipidemia, previous primary PCI to proximal and mid LAD because of anterolateral STEMI, presenting with syncope, and find out, through the debates around his treatment, how to use physiology in 2023.
